Biopharma testing company Eurofins Scientific, has acquired Alphora Research, a full service contract research, development and manufacturing organization (CRDMO) for complex and niche small molecule active pharmaceutical ingredients (APIs), based in Mississauga, Ontario, Canada. Alphora’s expertise in API development, testing and manufacturing provides Eurofins entry into the growing CRDMO market.

Alphora offers capabilities in multi-step syntheses, as well as the development of cytotoxic and highly potent APIs. It operates two fully integrated facilities to address a wide array of API challenges, providing a full spectrum of complex API development, testing and manufacturing services. The company supports biopharmaceutical companies from the preclinical phase through to commercialization of niche products, and complements Eurofins’ discovery and other biopharmaceutical testing activities.

“We are pleased to welcome Alphora to the Eurofins Group,” said Gilles Martin, chief executive officer, Eurofins. “Alphora’s competencies and footprint further strengthen Eurofins’ global leadership in the rapidly-growing biopharmaceutical testing market. We look forward to strengthening their portfolio and operating footprint by providing access to the full range of services and capabilities of the group.”